Junichiro Sonoda

This inventor holds 8 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignee: Genentech, Inc.. Active years: 2013-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Junichiro Sonoda. Retrieved from https://idiyas.com/inventor/junichiro-sonoda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 11)

% Patents Active = 87.5

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 62(Granted Patents)

Location History:

San Mateo, CA (US) (2013 - 2018)
Lafayette, CA (US) (2019)
South San Francisco, CA (US) (2018 - 2021)

Company Filing History:

8 out of 3,302

Genentech, Inc.

patents

Years Active: 2013-2021

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10882921 - Host cell comprising nucleic acids encoding bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 and antibody production (2021-01-05),

2. 10246518 - Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1 (2019-04-02),

3. 10208120 - Anti-FGFR2/3 antibodies and methods using same (2019-02-19),

4. 9884919 - Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 (2018-02-06),

5. 9873748 - Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 (2018-01-23),

6. 9845359 - FGFR1 agonists and methods of use (2017-12-19),

7. 9085626 - FGFR1 agonists and methods of use (2015-07-21),

8. 8535912 - Chimeric fibroblast growth factors with altered receptor specificity (2013-09-17),

I specialize in innovations, inventions, inventors, patent attorneys, assignees, and patents.

Profile summary based on public USPTO records.